OncoMatch/Clinical Trials/NCT07263438
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
Is NCT07263438 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for glioblastoma.
Treatment: Trimipramine · Cohort 1: Atezolizumab · Bevacizumab · Cohort 2: Atezolizumab · Cohort 2: Bevacizumab — This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not. The aim of the cohort 1 (patients without indication for surgery) is to analyze the clinical efficacy of this triple combination in recurrent glioblastoma. 48 patients will be registered. The aim of cohort 2 (patients with indication for surgery) is to confirm the level of trimipramine that can be achieved in the tumor tissue and cerebrospinal fluid collected during surgery. At least 5 patients will be registered. All patients will receive the combination treatment (trimipramine and atezolizumab associated with bevacizumab) for a maximum period of 2 years from registration. The treatment schedule is slightly different for the 2 cohorts because of the neurosurgical resection foreseen for cohort 2 and the requirement to start bevacizumab only after the surgery. After the end of treatment, all patients will be followed up for safety during 90 days from first treatment administration and then up to 3 years from registration.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
KARNOFSKY 70–100
Prior therapy
Must have received: radiation therapy — concurrent with temozolomide
standard (6 weeks radiotherapy [RT]) with concurrent & adjuvant temozolomide [TMZ] chemotherapy
Must have received: alkylating agent (temozolomide) — concurrent and adjuvant
standard (6 weeks radiotherapy [RT]) with concurrent & adjuvant temozolomide [TMZ] chemotherapy
Cannot have received: atezolizumab (atezolizumab)
Prior treatment with atezolizumab or any other immune checkpoint inhibitors
Cannot have received: immune checkpoint inhibitor
Prior treatment with atezolizumab or any other immune checkpoint inhibitors
Cannot have received: VEGF inhibitor (bevacizumab)
Prior treatment with bevacizumab or other Vascular Endothelial Growth Factor [VEGF] inhibitors or VEGF-receptor signaling inhibitors
Cannot have received: VEGF-receptor signaling inhibitor
Prior treatment with bevacizumab or other Vascular Endothelial Growth Factor [VEGF] inhibitors or VEGF-receptor signaling inhibitors
Lab requirements
Blood counts
neutrophil count ≥ 1.5 x 10^9/L, platelet count ≥ 100 x 10^9/L, hemoglobin ≥ 90 g/L
Kidney function
eGFR ≥ 45 mL/min/1.73 m2 (CKD-EPI formula)
Liver function
total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's syndrome ≤ 3.0 x ULN), AST and ALT and alkaline phosphatase ≤ 2.5 x ULN
Adequate bone marrow function: neutrophil count ≥ 1.5 x 10^9/L, platelet count ≥ 100 x 10^9/L, hemoglobin ≥ 90 g/L. Adequate hepatic function: total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's syndrome ≤ 3.0 x ULN), AST and ALT and alkaline phosphatase ≤ 2.5 x ULN. Adequate renal function: eGFR ≥ 45 mL/min/1.73 m2 (CKD-EPI formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify